NASDAQ:JAZZ Jazz Pharmaceuticals (JAZZ) Stock Price, News & Analysis $124.25 +1.28 (+1.04%) (As of 12/23/2024 05:45 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Jazz Pharmaceuticals Stock (NASDAQ:JAZZ) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Jazz Pharmaceuticals alerts:Sign Up Key Stats Today's Range$122.00▼$124.6350-Day Range$108.05▼$127.7452-Week Range$99.06▼$134.17Volume423,922 shsAverage Volume674,802 shsMarket Capitalization$7.51 billionP/E Ratio17.50Dividend YieldN/APrice Target$177.00Consensus RatingModerate Buy Company OverviewJazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.Read More… Jazz Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks97th Percentile Overall ScoreJAZZ MarketRank™: Jazz Pharmaceuticals scored higher than 97% of companies evaluated by MarketBeat, and ranked 40th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingJazz Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 13 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageJazz Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Jazz Pharmaceuticals' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth10.40% Earnings GrowthEarnings for Jazz Pharmaceuticals are expected to grow by 10.40% in the coming year, from $16.93 to $18.69 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jazz Pharmaceuticals is 17.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 113.02.Price to Earnings Ratio vs. SectorThe P/E ratio of Jazz Pharmaceuticals is 17.50, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 86.96.Price to Earnings Growth RatioJazz Pharmaceuticals has a PEG Ratio of 1.02. PEG Ratios around 1 indicate that a company is correctly valued.Price to Book Value per Share RatioJazz Pharmaceuticals has a P/B Ratio of 2.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.34% of the float of Jazz Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverJazz Pharmaceuticals has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Jazz Pharmaceuticals has recently increased by 11.26%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJazz Pharmaceuticals does not currently pay a dividend.Dividend GrowthJazz Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.0 / 5Environmental Score-1.96 Percentage of Shares Shorted7.34% of the float of Jazz Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverJazz Pharmaceuticals has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Jazz Pharmaceuticals has recently increased by 11.26%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.59 News SentimentJazz Pharmaceuticals has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Jazz Pharmaceuticals this week, compared to 10 articles on an average week.Search InterestOnly 10 people have searched for JAZZ on MarketBeat in the last 30 days. This is a decrease of -23% compared to the previous 30 days.MarketBeat Follows22 people have added Jazz Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 340% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Jazz Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $816,289.00 in company stock.Percentage Held by InsidersOnly 4.20% of the stock of Jazz Pharmaceuticals is held by insiders.Percentage Held by Institutions89.14% of the stock of Jazz Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Jazz Pharmaceuticals' insider trading history. Receive JAZZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address JAZZ Stock News HeadlinesJazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Sells $242,340.00 in StockDecember 5, 2024 | insidertrades.comJazz Pharmaceuticals: Should Sing A Better Tune In 2025December 23 at 1:03 PM | seekingalpha.comHow Low-Cost Stocks Generate Monthly IncomeAre you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE!December 24, 2024 | Darwin (Ad)Jazz Pharmaceuticals Shows Improved Relative Strength; Still Shy Of BenchmarkDecember 21 at 3:06 AM | msn.comJazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces CEO Succession PlanDecember 17, 2024 | finanznachrichten.deJazz Pharmaceuticals plc: Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 17, 2024 | finanznachrichten.deJazz Pharmaceuticals (JAZZ) Gets a Buy from TD CowenDecember 17, 2024 | markets.businessinsider.comJazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 17, 2024 | prnewswire.comSee More Headlines JAZZ Stock Analysis - Frequently Asked Questions How have JAZZ shares performed this year? Jazz Pharmaceuticals' stock was trading at $123.00 at the start of the year. Since then, JAZZ stock has increased by 1.0% and is now trading at $124.25. View the best growth stocks for 2024 here. How were Jazz Pharmaceuticals' earnings last quarter? Jazz Pharmaceuticals plc (NASDAQ:JAZZ) released its quarterly earnings data on Tuesday, November, 9th. The specialty pharmaceutical company reported $4.20 EPS for the quarter, topping the consensus estimate of $2.60 by $1.60. The specialty pharmaceutical company earned $838.12 million during the quarter, compared to analyst estimates of $829.98 million. Jazz Pharmaceuticals had a trailing twelve-month return on equity of 29.30% and a net margin of 11.60%. Does Jazz Pharmaceuticals have any subsidiaries? Jazz Pharmaceuticals subsidiaries include these companies: Cavion. Who are Jazz Pharmaceuticals' major shareholders? Jazz Pharmaceuticals' top institutional investors include Pacer Advisors Inc. (3.40%), State Street Corp (3.22%), Franklin Resources Inc. (1.85%) and Geode Capital Management LLC (1.84%). Insiders that own company stock include Bruce C Cozadd, Robert Iannone, Renee D Gala, Neena M Patil, Kim Sablich, Philip L Johnson, Finbar Larkin, Kenneth W O'keefe, Patrick G Enright, Christopher J Tovey, Mary Elizabeth Henderson, Peter Gray, Samantha Pearce, Rick E Winningham, Anne Oriordan, Mark Douglas Smith, Patricia Carr and Jennifer E Cook. View institutional ownership trends. How do I buy shares of Jazz Pharmaceuticals? Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Jazz Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Jazz Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings11/09/2021Today12/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:JAZZ CUSIPG5087110 CIK1232524 Webwww.jazzpharma.com Phone(531) 634-7800Fax353-1634-7850Employees2,800Year Founded2003Price Target and Rating Average Stock Price Target$177.00 High Stock Price Target$230.00 Low Stock Price Target$113.00 Potential Upside/Downside+42.5%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)$7.10 Trailing P/E Ratio17.50 Forward P/E Ratio7.34 P/E Growth1.02Net Income$414.83 million Net Margins11.60% Pretax Margin9.98% Return on Equity29.30% Return on Assets9.72% Debt Debt-to-Equity Ratio1.46 Current Ratio4.26 Quick Ratio3.74 Sales & Book Value Annual Sales$3.99 billion Price / Sales1.88 Cash Flow$28.63 per share Price / Cash Flow4.34 Book Value$59.36 per share Price / Book2.09Miscellaneous Outstanding Shares60,455,000Free Float57,916,000Market Cap$7.51 billion OptionableOptionable Beta0.57 Social Links 10 Best Stocks to Own in 2025Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio. Get This Free Report This page (NASDAQ:JAZZ) was last updated on 12/24/2024 by MarketBeat.com Staff From Our PartnersTiny Mineral, Massive Market OpportunityImagine a mineral so small it fits in the palm of your hand... yet its potential could transform the world's f...i2i Marketing Group, LLC | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored"This looks and feels like 2000," says investing legendOur senior analyst Dan Ferris says a new surprise crisis could begin at any moment... and this time, he says i...Stansberry Research | SponsoredA.I. Trading System Helps Some Traders Pocket $1,100 per DAY!What if I told you 60 seconds a day could completely change your life? This AI-powered trading syst...Prosper Trading Academy | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jazz Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Jazz Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.